AU2010229700A1 - Ascorbate-linked nanosystems for brain delivery - Google Patents

Ascorbate-linked nanosystems for brain delivery Download PDF

Info

Publication number
AU2010229700A1
AU2010229700A1 AU2010229700A AU2010229700A AU2010229700A1 AU 2010229700 A1 AU2010229700 A1 AU 2010229700A1 AU 2010229700 A AU2010229700 A AU 2010229700A AU 2010229700 A AU2010229700 A AU 2010229700A AU 2010229700 A1 AU2010229700 A1 AU 2010229700A1
Authority
AU
Australia
Prior art keywords
ascorbate
liposome
micelle
brain
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010229700A
Other languages
English (en)
Inventor
Tiziana Musacchio
Stefano Salmaso
Vladimir Torchilin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita degli Studi di Padova
Northeastern University Boston
Original Assignee
Of Padua, University of
Universita degli Studi di Padova
Northeastern University Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Of Padua, University of, Universita degli Studi di Padova, Northeastern University Boston filed Critical Of Padua, University of
Publication of AU2010229700A1 publication Critical patent/AU2010229700A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2010229700A 2009-03-26 2010-03-26 Ascorbate-linked nanosystems for brain delivery Abandoned AU2010229700A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16357709P 2009-03-26 2009-03-26
US61/163,577 2009-03-26
PCT/US2010/028872 WO2010111620A1 (fr) 2009-03-26 2010-03-26 Nanosystèmes liés à l'ascorbate pour administration cérébrale

Publications (1)

Publication Number Publication Date
AU2010229700A1 true AU2010229700A1 (en) 2011-10-27

Family

ID=42781556

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010229700A Abandoned AU2010229700A1 (en) 2009-03-26 2010-03-26 Ascorbate-linked nanosystems for brain delivery

Country Status (5)

Country Link
EP (1) EP2410992A4 (fr)
CN (1) CN102458365A (fr)
AU (1) AU2010229700A1 (fr)
CA (1) CA2756581A1 (fr)
WO (1) WO2010111620A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372250B1 (en) * 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
WO2008112565A2 (fr) * 2007-03-09 2008-09-18 Anthony Manganaro Méthode et composition pour traiter le cancer

Also Published As

Publication number Publication date
CN102458365A (zh) 2012-05-16
WO2010111620A1 (fr) 2010-09-30
CA2756581A1 (fr) 2010-09-30
EP2410992A4 (fr) 2013-09-11
EP2410992A1 (fr) 2012-02-01

Similar Documents

Publication Publication Date Title
US20230381338A1 (en) Polyglutamated antifolates and uses thereof
US11534498B2 (en) Polyglutamated antifolates and uses thereof
ES2905498T3 (es) Medicamento con afinidad encapsulado en liposoma
US9474716B2 (en) SiRNA phospholipid conjugate
CN104853747A (zh) 用于体内递送的脂质体
US20110190623A1 (en) Thermally-activatable liposome compositions and methods for imaging, diagnosis and therapy
US20210330696A1 (en) A high capacity platform for immunogenic cancer cell death
Tomsen-Melero et al. Liposomal formulations for treating lysosomal storage disorders
TW201412344A (zh) 經靶向之脂質體
AU2010229700A1 (en) Ascorbate-linked nanosystems for brain delivery
WO2020232701A1 (fr) Système d'administration de médicament à nanoliposome marqué par un monosaccharide, sa méthode de préparation et son utilisation en tant que vecteur d'administration de ciblage pour un médicament
US20240033374A1 (en) Nano-structural Protein Degradation Tool, Use, and Preparation Method thereof, and Lipid-based Protein Degradation Tool, Use, and Preparation Method thereof
US20230068750A1 (en) Methods & Systems for Controlled Release of Drug Cargo via ATP- Responsive Liposomes
TWI734987B (zh) 單醣標記之奈米脂質體藥物遞送系統，其製法及其作為藥物靶定遞送載體之應用
US20210379214A1 (en) Phospholipid-Free Small Unilamellar Vesicles (PFSUVS) for Drug Delivery
AU2024205501A1 (en) Liposome encapsulated affinity drug
OA19187A (en) Polyglutamated antifolates and uses thereof.
OA19456A (en) Liposome encapsulated affinity drug.

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period